News

CIDRAP13d
FDA approves Merck RSV monoclonal antibody shot for infants
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...
PharmExec10d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
Fierce Pharma13d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Healio12d
FDA approves clesrovimab for preventing RSV in infants
The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...
FDA approves new RSV treatment for infants
CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
The American Journal of Managed Care13d
FDA Approves Clesrovimab to Prevent RSV in Infants During First Season
The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.